Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; 1 of the 1 sources its claims cite were checked for support.

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

Open access

Abstract

The global prevalence of type 2 diabetes and obesity, affecting over 507 million 1 and 890 million 2 individuals, respectively, underscores the urgent need for more effective treatments. The most successful treatments currently available include glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), exemplified by semaglutide (approved in 2017, $19.9 billion sales in 2023) 3 and tirzepatide (approved in 2022, $5.3 billion sales in 2023) 4 . Unlike semaglutide which solely activates GLP-1R (one of the three pivotal receptors regulating glucose homeostasis), tirzepatide also activates glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) to enhance metabolic benefits with reduced side-effects 5 . However, both medications do not target glucagon (GCG) receptor (GCGR). Recently, retatrutide (also known as LY3437943) 6 , 7 , 8 , 9 has shown impressive efficacy in obesity treatment through triple agonism at GLP-1R, GIPR and GCGR. Compared to the corresponding endogenous hormones, retatrutide is more potent at GIPR by a factor of 8.9, and less potent at GCGR and GLP-1R by factors of 0.3 and 0.4, respectively 7 (Fig. 1a ). Retatrutide induces greater body weight losses in obese mice than tirzepatide, due to an increased energy expenditure through GCGR activation 6 . In a phase 2 obesity trial, retatrutide demonstrated an average weight loss of 17.5% at 24 weeks and 24.2% at 48 weeks in the 12 mg dose group 7 . Additionally, in a phase 2 trial targeting type 2 diabetes, retatrutide demonstrated significant improvements in glycemic control and substantial weight reduction, maintaining a safety profile comparable to certain approved GLP-1RAs 8 (Supplementary Table S1 ). These results support the rationale of developing retatrutide as an alternative to semaglutide and/or tirzepatide 5 . Indeed, phase 3 clinical trials of retatrutide for type 2 diabetes, non-alcoholic fatty liver disease, and obesity are presently underway (Supplementary Table S2 ) 10 . To understand the multiplexed pharmacological actions of retatrutide, we used cryo-electron microscopy (cryo-EM) to determine the structures of GLP-1R, GIPR and GCGR bound to retatrutide. Fig. 1: Molecular recognition of retatrutide by GLP-1R, GIPR and GCGR. a Retatrutide (LY3437943) possesses combinatorial agonism at GLP-1R, GIPR and GCGR, distinct from the approved GLP-1R agonists (such as semaglutide and exenatide) and GLP-1R/GIPR dual agonist tirzepatide. b Cryo-EM maps of retatrutide-bound GLP-1R (left), GIPR (middle) and GCGR (right) in complex with G s . The colored cryo-EM density maps are shown at the thresholds of 0.110, 0.107 and 0.134 for the retatrutide–GLP-1R–G s , retatrutide–GIPR–G s and retatrutide–GCGR–G s complexes, respectively. The GLP-1R is shown in dodger blue, GIPR in forest green, GCGR in hot pink, GLP-1R-bound retatrutide in gold, GIPR-bound retatrutide in orange, GCGR-bound retatrutide in coral, Gα s in yellow, Gβ subunit in cyan, Gγ subunit in blue and Nb35 in gray. c Structural comparison of retatrutide–GLP-1R, retatrutide–GIPR and retatrutide–GCGR. Receptor ECD and G protein are omitted for clarity. d Schematic diagram of retatrutide recognition mode in GLP-1R, GIPR and GCGR, described by fingerprint strings encoding different interaction types of the surrounding residues in each receptor. Close-up views of the interactions are shown for the N-terminal nine residues of retatrutide. The polar contacts are shown as black dashed lines. Receptor residues are labeled with class B1 GPCR numbering and colored sky blue for salt bridge, red for hydrogen bond, orange for stacking and gray for hydrophobic interactions. Residues that show no interaction with retatrutide are displayed as white circles. e Effects of GLP-1R (top), GIPR (middle), and GCGR (bottom) mutations on retatrutide-induced cAMP accumulation. Bars represent differences in the calculated retatrutide potency (pEC 50 ) for representative mutants relative to the wild-type (WT). Data are colored according to the extent of effect. Data shown are from at least three independent experiments performed in quadruplicate. All data were analyzed by one-way ANOVA and Dunnett’s test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. N.D., values that could not be determined due to incomplete curve fits. f The distinct secondary structures of the ECL1 of GLP-1R, GIPR and GCGR. g Amino acid sequence comparison of endogenous hormones, representative dual and triple agonists. Residues are colored according to sequence conservation among GLP-1, GIP and GCG. Aib α-amino isobutyric acid, αMeL α-methyl L -leucine. Semaglutide, tirzepatide, peptide 20 (MAR423) and retatrutide are acylated with various fatty diacid moieties via a linker connected to the lysine residues at the positions of 20, 20, 10 and 17, respectively. h Comparison of the interactions between GLP-1R ECL1 and representative peptide agonists including retatrutide, GLP-1 (PDB ID: 6X18), semaglutide (PDB ID: 7KI0)

Overview

CoChat Summary

## TL;DR

This paper reports cryo-EM structures of retatrutide bound to GLP-1R, GIPR, and GCGR, explaining how one peptide can act as a triple agonist across these three class B GPCRs. The authors combine structural comparisons with mutagenesis to show that shared core interactions plus receptor-specific extracellular loop conformations underlie retatrutide’s balanced receptor recognition.

## Key findings

  • The authors determined three retatrutide–receptor–Gs structures by single-particle cryo-EM with overall resolutions of 2.68 Å (GLP-1R), 3.26 Å (GIPR), and 2.84 Å (GCGR).
  • Across the three complexes, retatrutide adopts a single continuous helix; its N-terminal residues 1–13 penetrate the TMD core, while residues 14–30 interact with the receptor ECD and extracellular tips.
  • The three receptor-bound structures are highly similar overall, with Cα RMSD values of 0.88–0.93 Å, but show receptor-specific differences in ECL1 and the extracellular tips of TM1/TM3/TM7 that tune peptide positioning.
  • Mutagenesis supported key contact residues: for example, E6.53bA reduced retatrutide potency by 3.6-fold (GLP-1R), 1.6-fold (GIPR), and 8.3-fold (GCGR); E/D7.42bA reduced potency by 71.6-fold (GIPR) and 5.8-fold (GCGR).
  • Receptor-specific mutations also had large effects, including R196ECL1Y in GIPR, which diminished retatrutide potency by 107.7-fold, and Y1381.36bA in GCGR, which decreased potency by 26.9-fold.

## Methods

  • The study used single-particle cryo-electron microscopy with the NanoBiT tethering strategy to solve structures of retatrutide–GLP-1R–Gs, retatrutide–GIPR–Gs, and retatrutide–GCGR–Gs.
  • Structural modeling and comparison were used to identify shared interactions and receptor-specific contacts, including extracellular loop conformations and peptide orientation differences.
  • The authors performed site-directed mutagenesis and measured effects on retatrutide-induced cAMP signaling/accumulation to test the structural hypotheses.

## Limitations

  • Several regions were poorly resolved and not modeled, including parts of the GCGR ECD, the GLP-1R stalk (residues 130–135), GIPR ECL1 (residues 202–207), and ICL3 segments in GLP-1R and GIPR.
  • The paper makes evident, but does not explicitly frame as a limitation, that the analysis is structural and mutational rather than a comprehensive in vivo pharmacology study.
  • Not stated in the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41421-024-00700-0

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Molecular recognition of retatrutide by GLP-1R, GIPR and GCGR. a Retatrutide (LY3437943) possesses combinatorial agonism at GLP-1R, GIPR and GCGR, distinct from the approved GLP-1R agonists (such as semaglutide and exenatide) and GLP-1R/GIPR dual agonist tirzepatide. b Cryo-EM maps of retatrutide-bound GLP-1R (left), GIPR (middle) and GCGR (right) in complex with Gs. The colored cryo-EM density maps are shown at the thresholds of 0.110, 0.107 and 0.134 for the retatrutide–GLP-1R–Gs, retatrutide–GIPR–Gs and retatrutide–GCGR–Gs complexes, respectively. The GLP-1R is shown in dodger blue, GIPR in forest green, GCGR in hot pink, GLP-1R-bound retatrutide in gold, GIPR-bound retatrutide in orange, GCGR-bound retatrutide in coral, Gαs in yellow, Gβ subunit in cyan, Gγ subunit in blue and Nb35 in gray. c Structural comparison of retatrutide–GLP-1R, retatrutide–GIPR and retatrutide–GCGR. Receptor ECD and G protein are omitted for clarity. d Schematic diagram of retatrutide recognition mode in GLP-1R, GIPR and GCGR, described by fingerprint strings encoding different interaction types of the surrounding residues in each receptor. Close-up views of the interactions are shown for the N-terminal nine residues of retatrutide. The polar contacts are shown as black dashed lines. Receptor residues are labeled with class B1 GPCR numbering and colored sky blue for salt bridge, red for hydrogen bond, orange for stacking and gray for hydrophobic interactions. Residues that show no interaction with retatrutide are displayed as white circles. e Effects of GLP-1R (top), GIPR (middle), and GCGR (bottom) mutations on retatrutide-induced cAMP accumulation. Bars represent differences in the calculated retatrutide potency (pEC50) for representative mutants relative to the wild-type (WT). Data are colored according to the extent of effect. Data shown are from at least three independent experiments performed in quadruplicate. All data were analyzed by one-way ANOVA and Dunnett’s test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. N.D., values that could not be determined due to incomplete curve fits. f The distinct secondary structures of the ECL1 of GLP-1R, GIPR and GCGR. g Amino acid sequence comparison of endogenous hormones, representative dual and triple agonists. Residues are colored according to sequence conservation among GLP-1, GIP and GCG. Aib α-amino isobutyric acid, αMeL α-methyl L-leucine. Semaglutide, tirzepatide, peptide 20 (MAR423) and retatrutide are acylated with various fatty diacid moieties via a linker connected to the lysine residues at the positions of 20, 20, 10 and 17, respectively. h Comparison of the interactions between GLP-1R ECL1 and representative peptide agonists including retatrutide, GLP-1 (PDB ID: 6X18), semaglutide (PDB ID: 7KI0), exenatide (PDB ID: 7LLL), tirzepatide (PDB ID: 7FIM) and peptide 20 (PDB ID: 7VBH). i Comparison of the interactions between GIPR ECL1 and representative peptide agonists including retatrutide, GIP (PDB ID: 7DTY), tirzepatide (PDB ID: 7FIY) and peptide 20 (PDB ID: 7FIN). j Comparison of the interactions between GCGR ECL1 and representative peptide agonists including retatrutide, GCG (PDB ID: 6LMK) and peptide 20 (PDB ID: 7V35).
Fig. 1 Molecular recognition of retatrutide by GLP-1R, GIPR and GCGR. a Retatrutide (LY3437943) possesses combinatorial agonism at GLP-1R, GIPR and GCGR, distinct from the approved GLP-1R agonists (such as semaglutide and exenatide) and GLP-1R/GIPR dual agonist tirzepatide. b Cryo-EM maps of retatrutide-bound GLP-1R (left), GIPR (middle) and GCGR (right) in complex with Gs. The colored cryo-EM density maps are shown at the thresholds of 0.110, 0.107 and 0.134 for the retatrutide–GLP-1R–Gs, retatrutide–GIPR–Gs and retatrutide–GCGR–Gs complexes, respectively. The GLP-1R is shown in dodger blue, GIPR in forest green, GCGR in hot pink, GLP-1R-bound retatrutide in gold, GIPR-bound retatrutide in orange, GCGR-bound retatrutide in coral, Gαs in yellow, Gβ subunit in cyan, Gγ subunit in blue and Nb35 in gray. c Structural comparison of retatrutide–GLP-1R, retatrutide–GIPR and retatrutide–GCGR. Receptor ECD and G protein are omitted for clarity. d Schematic diagram of retatrutide recognition mode in GLP-1R, GIPR and GCGR, described by fingerprint strings encoding different interaction types of the surrounding residues in each receptor. Close-up views of the interactions are shown for the N-terminal nine residues of retatrutide. The polar contacts are shown as black dashed lines. Receptor residues are labeled with class B1 GPCR numbering and colored sky blue for salt bridge, red for hydrogen bond, orange for stacking and gray for hydrophobic interactions. Residues that show no interaction with retatrutide are displayed as white circles. e Effects of GLP-1R (top), GIPR (middle), and GCGR (bottom) mutations on retatrutide-induced cAMP accumulation. Bars represent differences in the calculated retatrutide potency (pEC50) for representative mutants relative to the wild-type (WT). Data are colored according to the extent of effect. Data shown are from at least three independent experiments performed in quadruplicate. All data were analyzed by one-way ANOVA and Dunnett’s test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. N.D., values that could not be determined due to incomplete curve fits. f The distinct secondary structures of the ECL1 of GLP-1R, GIPR and GCGR. g Amino acid sequence comparison of endogenous hormones, representative dual and triple agonists. Residues are colored according to sequence conservation among GLP-1, GIP and GCG. Aib α-amino isobutyric acid, αMeL α-methyl L-leucine. Semaglutide, tirzepatide, peptide 20 (MAR423) and retatrutide are acylated with various fatty diacid moieties via a linker connected to the lysine residues at the positions of 20, 20, 10 and 17, respectively. h Comparison of the interactions between GLP-1R ECL1 and representative peptide agonists including retatrutide, GLP-1 (PDB ID: 6X18), semaglutide (PDB ID: 7KI0), exenatide (PDB ID: 7LLL), tirzepatide (PDB ID: 7FIM) and peptide 20 (PDB ID: 7VBH). i Comparison of the interactions between GIPR ECL1 and representative peptide agonists including retatrutide, GIP (PDB ID: 7DTY), tirzepatide (PDB ID: 7FIY) and peptide 20 (PDB ID: 7FIN). j Comparison of the interactions between GCGR ECL1 and representative peptide agonists including retatrutide, GCG (PDB ID: 6LMK) and peptide 20 (PDB ID: 7V35).CC BY · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 0 Not checked · 32 Own results and interpretations

11 more claims

Create a free account to see all 33 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 1
  • It may state two separate claims as one. 17
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 11 references

Cited by

See all 32

Metadata

Authors
Li, W., Zhou, Q., Cong, Z., Yuan, Q., Li, W., Zhao, F., Xu, H. E., Zhao, L.-H., Yang, D., & Wang, M.-W.
Affiliations
  • Shanghai Medical College of Fudan University (CN)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Yang, Dehua
  • Wang, Ming-Wei
Venue
Cell Discovery
Published
2024-07-17
Volume
10
Issue
1
Pages
77-77
ISSN
2056-5968 (ISSN-L)
OpenAlex
W4400737015
Cited by
32
References
11
Citations by year
2026: 12 · 2025: 15 · 2024: 5
FWCI
4.34
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Discovery (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • Fudan University
  • State Key Laboratory of Drug Research
  • Program of Shanghai Academic Research Leader
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
retatrutide, GLP-1 receptor, GIP receptor, glucagon receptor, obesity treatment, type 2 diabetes, semaglutide, tirzepatide, weight loss, energy expenditure, glucose homeostasis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. https://app.cochat.ai/papers/10.1038/s41421-024-00700-0
The paper
Li, W., Zhou, Q., Cong, Z., Yuan, Q., Li, W., Zhao, F., Xu, H. E., Zhao, L.-H., Yang, D., & Wang, M.-W. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. https://doi.org/10.1038/s41421-024-00700-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.